This study aimed to evaluate the efficacy and safety of the 308-nm excimer lamp in resistant AA treated with topical minoxidil .

Alopecia areata (AA) is a chronic, nonscarring, T-cell mediated autoimmune disease, presenting with localized or diffuse hair fall in hair-bearing areas. Approximately 1.7% of the population experience an episode of AA during their lifetime. Both sexes are equally affected, and most new cases are recorded below the age of 30 years . Excimer laser using high-dose monochromatic UV radiation can trigger apoptosis and induce immunological suppression through altering cytokine production such as IL-4, IL-10, prostaglandin E2, platelet-activating factor, and cis-urocanic acid. Benefits have only been seen with localized patches of AA, and regrowth of hair occurs only in treated areas .

Inclusion Criteria:

• ● Having multiple patches of AA.

  • Duration of alopecia >1 year
  • No topical or systemic treatment for the last 4 months
  • Agreement to regular visits for treatment and follow-up.

Exclusion Criteria:

• ● A single form of AA.

  • Alopecia for <1 year.
  • Being on other modalities of treatment.
  • Treatment within the last 4 months.
  • Photosensitive disorders.
  • Pregnancy or breastfeeding.

patients take 24 sessions with excimer light for 3 months